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Background: In patients with asthma, medication adherence is a voluntary behavior that can be affected by
numerous factors. Depression is an important co-morbidity in adolescents with asthma that may significantly impact
their controller medication adherence and other asthma-related outcomes. The modifying effect of depressive
symptoms on an asthma intervention’s ability to improve asthma controller medication adherence among urban
adolescents with asthma has not yet been reported.
Objective: To assess self-reported symptoms of depression as an effect modifier of the relationship between
randomization group and controller medication adherence at 6-month follow-up.
Methods: These analyses use data from a randomized controlled trial (RCT) conducted in Detroit high schools to
evaluate a tailored asthma management program. The intervention included referrals to school or community
resources for students reporting symptoms of depression and other issues. “Elevated depressive symptoms” was
defined as a positive answer to ≥ 5 of 7 questions from a validated tool included on the baseline questionnaire.
Self-reported adherence to controller medication was collected at intervention onset (session 1) and at 6-month
follow up. Analyses were restricted to students with report of a controller medication at baseline. Logistic regression
was used to assess elevated depressive symptoms as an effect modifier of the relationship between randomization
group and 6-month adherence.
Results: Of the 422 students enrolled in the RCT, a controller medication was reported at intervention onset by n = 123
adolescents (29%). Analyzing this group, we observed an interaction between elevated depressive symptoms and
adherence (p = 0.073). Stratified analysis showed better adherence in treatment group adolescents meeting criteria for
elevated depressive symptoms at baseline as compared to the control group (adjusted Odds Ratio [aOR] = 9.50;
p = 0.024). For adolescents without elevated depressive symptoms at baseline, differences in adherence by
group assignment did not reach statistical significance (aOR 1.40, p = 0.49).
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Conclusions: In this sample of students reporting controller medications at baseline, report of elevated
depressive symptoms at baseline and randomization to the intervention group was associated with significantly
better adherence at 6-month follow up when compared to that of a control group. Larger studies are needed to
evaluate the impact of depression on the relationship between adherence and asthma intervention effectiveness.
Keywords: Asthma, Depression, Medication adherence, Randomized controlled trial, Self-management,
Adolescents, UrbanBackground
There is a significantly higher prevalence of asthma in
urban African American and Latino adolescents and these
groups are known to have worse asthma-related outcomes
than their White counterparts [1]. Asthma control is
impacted by a number of factors, including adherence
to prescribed regimens. Adherence, as per its definition,
is an “active, voluntary and collaborative involvement of
the patient in a mutually acceptable course of behavior
to produce a therapeutic result”. Adherence is influenced
by a number of internal and external factors including
patient beliefs and attitudes, disease and therapy-related
factors, health system characteristics, and socioeconomic
factors [2]. According to the literature, urban adolescents
with asthma in general have poor adherence to asthma
controller medications [3]. Studies using electronic moni-
toring of controller medication adherence in adolescents
[4,5] have shown 40-50% adherence, with significantly lower
rates of adherence in African American adolescents [6].
Depression is a known co-morbidity of asthma; however,
few studies provide estimates of depression as co-morbidity
in adolescents with asthma. Existing reports suggest the
prevalence of depression among adolescents with asthma
ranges from 7.2 to 16.3% [7-9]. Depression may impact
quality of life in adolescents with asthma. In a previous
analysis of Puff City data, we have shown that depressive
symptoms significantly impact emotional quality of life
[10]. Depression has been associated with medication
adherence in adults and in diseases other than asthma
[11-13], but the impact of depression on asthma interven-
tion effectiveness with regard to controller medication ad-
herence has not been explored in urban adolescents.
The present analyses explore the impact of elevated de-
pressive symptoms at baseline on the ability of an asthma
intervention to improve adherence to controller medica-
tions at 6-month follow-up, among urban teens with
asthma. The intervention upon which these analyses
are based is Puff City, a computer-tailored, web-based
program for urban teens with asthma, originally developed
and tested in 2001 [14]. An enhanced version was evaluated
in Detroit high schools using a randomized controlled trial
conducted from 2007–2011 [15]. The subgroup analyses
reported here include urban teenagers that were enrolledin the 2007 – 2011 RCT of Puff City, and reported con-
troller medication(s) at intervention onset.
Methods
The details of the Puff City randomized controlled trial
have been published previously [14-16]. Briefly, to iden-
tify students with asthma or asthma symptoms, care-
givers of all 9th through 12th grade students of six
Detroit public high schools were notified by mail of a
Lung Health Questionnaire (LHQ) to be administered
during an English class. Parents could opt out of having
their child complete the LHQ by signing and returning
the letter to the school or by contacting the school. Eli-
gibility to participate in the RCT was based on LHQ re-
sponses. To be eligible, the students had to have a
physician diagnosis of asthma accompanied by one or
more of the following: presence of daytime and/or night-
time symptoms in the last 30 days, medication use for
asthma symptoms in the last 30 days, and ≥1 refill(s) of
beta-agonists in the last 1 year. Adolescents without a
physician diagnosis of asthma were also eligible to partici-
pate if they had positive responses to items selected from
the International Study of Asthma and Allergies in Child-
hood (ISAAC) [17], and had symptom frequencies similar
to those used in EPR 2 and 3 (e.g., for “mild persistent
asthma” criteria from EPR3 include “symptoms ≥ 2 days/
week, nighttime awakening ≥ 3-4x/month, and interfer-
ence with normal activities = minor limitation”) [18,19].
Students identified as eligible for the RCT based on the
above criteria were mailed an invitation to participate in
the RCT, along with forms for parental written consent
and student written assent. Once consent and assent
were obtained, a study ID was assigned and entered into
the study database. In this way, no student data was
shared with investigators until appropriate informed
consent was obtained [15]. After a baseline assessment,
consenting students were randomized into a treatment
or control group (Figure 1). The treatment group under-
went a total of 4 computer-based tailored online asthma
management sessions that featured topics such as asthma
management behaviors (including asthma medication use
and adherence, having a rescue inhaler nearby, and
smoking cessation and/or reduction), trigger avoidance
Figure 1 CONSORT Flow diagram for the school-based Puff City randomized controlled trial showing the screening of participants and
breakdown of treatment and control groups.
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provided access to existing, generic asthma education
websites during 4 computer sessions of duration similar
to that of the treatment group. Asthma controller medi-
cations that were prescribed by a physician were re-
quested from both treatment and control group
students at the onset of intervention session 1 using a
medication selection module designed for this purpose.
The module displayed pictures of medications listed in
the Health plan Employer Data and Information Set
(HEDIS) measure for asthma called Use of Appropriate
Medications for People with Asthma [20], and included
corticosteroids, inhaled steroid combinations, leukotri-
ene receptor antagonists, mast cell stabilizers, andantibody inhibitors. Participants were asked to select
the asthma medications they were currently taking, if
any. All medications reported by the participant were cat-
egorized as “controller” or “rescue”.
A referral coordinator was also part of the intervention.
The referral coordinator’s task was to assess, refer, and
follow-up with students in the intervention group identi-
fied to be at-risk of a serious event through a risk assess-
ment report generated by the data management system
[16]. Students were contacted if they reported sharing
asthma medication, severe asthma symptoms, lack of
physician or health insurance, and/or depressive symp-
toms. Treatment group students with depressive symp-
toms were usually referred to school-based resources (e.g.,
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clinic); and to community-based resources when school
resources were not available.
As part of the study protocol, participants received
mail and telephone reminders to login to the program
and complete a follow-up survey scheduled for 6-months
post-baseline. Survey questions collected information
on asthma outcomes (e.g., symptom-days, symptom-nights,
days of restricted activity), as well as information on
controller medication adherence. Follow-up questions
were the same for treatment and control group students, al-
though treatment group students could receive add-
itional “booster” messages based on responses to the 6-
month survey questions. This study was approved by
the Institutional Review Boards of the participating in-
stitutions (IRB Protocol #4579) and by the Detroit Public
Schools Office of Research, Evaluation and Assessment.
Study definitions
Depressive symptoms were reported at baseline using 7
questions from the Diagnostic Predictive Scale (DPS) that
enquires about symptoms typically associated with depres-
sion in the preceding 6-months [21]. The DPS is a result
of adaptations to the Diagnostic Interview Schedule for
Children (DISC), which is a structured diagnostic in-
strument specifically designed for use by non-clinicians
[22]. The fourth version (DISC-IV) was further adapted
to create several shorter scales (including the Diagnostic
Predictive Scale used in this study) for use as screening
tools for various psychiatric diagnoses, including depres-
sion [21]. The DPS has been tested in various populations
and has been reported to be an efficient and reliable
screening tool [23,24] for children between the ages of 8
to 18 years. Using published cutoff scores established by
Lucas et al. [21], elevated depressive symptoms was
defined as a positive response to 5 or more questions
on the DPS. Adherence to asthma controller medication
was defined as self-reported use of the medication on 5 or
more days out of last 7 days. Controller medication adher-
ence collected at the 6-month follow-up was the primary
outcome of these analyses.
Statistical analysis
Since the goal of these analyses was to assess the effect
of depression on the ability of the intervention to improveTable 1 Prevalence of elevated depressive symptoms and con
(Session 1) for teens in the treatment and control groups
Trea
% of teens with elevated depressive symptoms at baseline (n) 20.7
Core behavior and report of medication at session 1
Controller medication, adherent≥ 5 of last 7 days 24.1
Controller medication, not adherent < 5 of last 7 days 75.9controller medication adherence, analyses were restricted
to the group of adolescents reporting asthma controller
medications at baseline. Logistic regression was used to
assess elevated depressive symptoms as an effect modi-
fier of the relationship between randomization group and
controller medication adherence at 6-months using the
p value of <0.10 as indicating the presence of effect
modification and the need to present stratum-specific
results [25]. Baseline controller medication adherence
was included as a covariate in all logistic regression
models. Adjusted odds ratios (aOR) and corresponding
95% confidence intervals were calculated to describe the
association between randomization group and control-
ler medication adherence at 6-months.
Results
The breakdown of the study population is shown in
Figure 1. Baseline assessment was completed by 422
adolescents. A total of 58 adolescents in the treatment
group (28.4%) and 65 in the control group (29.8%) reported
a controller medication at the start of the intervention
(Table 1). Among those reporting use of a controller
medication at intervention onset, the percentage of ado-
lescents in the treatment and control groups meeting
criteria for elevated depressive symptoms was 20.7%
(n = 12) and 24.6% (n = 16), respectively, p = 0.60.
Controller medication adherence for treatment and con-
trol group students at intervention onset was 24.1% (n = 14)
and 27.7% (n = 18) respectively.
At the 6-month follow up, after adjusting for baseline
adherence, 22 adolescents in the treatment group (37.9%)
reported controller medication adherence, as compared to
17 adolescents in the control group (26.2%) (Table 2).
The relationship between elevated depressive symptoms
at baseline and controller medication adherence met
criterion for the presence of an interaction (p = 0.073)
[16,25]. Stratified analysis is presented in Table 3. For
adolescents that reported elevated depressive symptoms
at baseline, 7/12 (58.3%) in the treatment group reported
being adherent to their controller medication at the
6-month follow-up, while 2/16 (12.5%) were adherent
in the control group, aOR = 9.5; p = 0.024. For adolescents
that did not report depressive symptoms at baseline,
medication adherence at 6-month follow-up was only
slightly higher among students randomized to the treatmenttroller medication adherence at intervention onset
tment N = 58 Control N = 65 Odds ratio (95% CI) p value
(12) 24.6 (16) 0.80 (0.34, 1.87) 0.60
(14) 27.7 (18) 0.83 (0.37, 1.87) 0.65
(44) 72.3 (47)
Table 2 Comparison of controller medication adherence at 6 month follow-up for by randomization group for students
included in the analysis sample*
Treatment N = 58 Control N = 65 Adjusted** odds ratio (95% CI) p value
Core behavior at 6 months**
Controller medication, adherent≥ 5 of last 7 days 37.9 (22) 26.2 (17) 2.10 (0.89, 4.92) 0.089
Controller medication, not adherent < 5 of last 7 days 62.1 (36) 73.8 (48)
*Students enrolled in Puff City and reporting a controller medication at baseline assessment. **Adjusted for controller medication adherence at start of intervention.
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6-month follow up, aOR = 1.4; p = 0.49.
Discussion
The Puff City program uses tailoring to promote positive
behaviors such as regular use of controller medications
by providing personalized health messages to help ad-
dress the adolescents’ beliefs, attitudes and barriers to
behavior change in addition to referrals from an asthma
referral coordinator. Results of these subgroup analyses
suggest that the effectiveness of a program to improve
adherence to controller medications in urban adolescents
with asthma may be significantly impacted by the pres-
ence of depressive symptoms. For this reason, it may be
worthwhile to address depressive symptoms when treating
asthma in order to improve asthma-related outcomes. We
did note a modicum of improvement in medication adher-
ence among treatment group students who did not meet
criteria for elevated depression at baseline, but a compari-
son to the control group did not reach statistical signifi-
cance. Therefore, interventions to improve controller
medication adherence in adolescents with and without de-
pressive symptoms may still be needed. Our results may
have important implications for designing future interven-
tions specifically targeting improvements in controller
medication adherence in urban adolescents with asthma.
Other investigators have also found depression to be a
significant determinant of medication adherence in sev-
eral disorders other than asthma. A recent meta-analysis
of 31 studies (18,425 participants) of adults with various
chronic conditions reported a 1.76 times greater oddsTable 3 Comparison of controller medication adherence at 6
elevated depressive symptoms, for students included in the a
Meet criteria for elevated depressive symptoms at baseline:
Core behavior at 6 months**
Controller medication, adherent≥ 5 of last 7 days 5
Controller medication, not adherent < 5 of last 7 days 4
Do not meet criteria for elevated depressive symptoms at baseline:
Core behavior at 6 months*
Controller medication, adherent≥ 5 of last 7 days 3
Controller medication, not adherent < 5 of last 7 days 6
*Students enrolled in Puff City and reporting a controller medication at baseline assessfor non-adherence in depressed patients [26]. Another
report suggests that approximately 20 to 30 percent of
prescriptions are never filled (primary non-adherence)
and 50% of medications prescribed for chronic diseases
are not taken as prescribed [2]. Medication non-adherence
is associated with higher downstream health care costs
[27], and can be reduced by improved self-management
of chronic disorders such as asthma. We are unaware of
any other study that has reported the effectiveness of
asthma interventions on controller medication adher-
ence among adolescents with depressive symptoms.
Other co-morbidities have been observed in asthma.
Besides depressive symptoms, adolescents with asthma
have also been found to have a higher prevalence of anxiety
disorder [28] and internalizing behaviors [29]. These
are linked through several psychological and biological
factors such as the stress of asthma management, medi-
cation regimens, and avoidance of allergic triggers; or
through cognitive responses to asthma symptoms such
as learned helplessness or fear of bodily sensations. In
the case of adolescents, having asthma symptoms may
induce social anxiety (due to concern for negative evalu-
ation by peers) that can significantly impact asthma-related
outcomes [30].
The overall rate of controller medication use in this
study was low (29% at baseline) resulting in a small sam-
ple available for analyses. There are additional limita-
tions to this study. First, we used self-reported measures
of asthma controller medication adherence, which can
have questionable validity and reliability [31,32]. We note
that self-report of asthma controller medication adherencemonth follow-up by randomization group and by baseline
nalysis sample*
Treatment Control Adjusted** odds ratio (95% CI) p value
8.3 (7) 12.5 (2) 9.50 (1.35, 67.0) 0.024
1.7 (5) 87.5 (14)
2.6 (15) 30.6 (15) 1.40 (0.53, 3.67) 0.49
7.4 (31) 69.4 (34)
ment. **Adjusted for controller medication adherence at start of intervention.
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and Nutrition Examination Survey (NHANES) [33], and
National Asthma Survey (NAS) [34]. Second, we cannot
determine which component of the intervention was in-
strumental in motivating participants to be more adher-
ent, i.e., depressed students received tailored messages
about controller medication through the online program
in addition to referrals made by the asthma referral coord-
inator for their depressive symptoms. Moreover, we can-
not confirm that students followed up on referrals from
the asthma referral coordinator and cannot report on the
therapies or advice these students may or may not have
received from these referrals. Consequently, we cannot
speculate on the mechanism by which controller medica-
tion adherence was improved among students reporting
depressive symptoms at baseline. Third, a sustained inter-
vention effect for controller medication adherence post
6-month follow-up is unknown. Finally, because this
study was done in urban adolescents with asthma, the
results may only be applicable to other populations with
characteristics similar to that of our study population.
Given the limitations of this study, additional analyses
in larger study samples are needed.
Conclusions
In these subgroup analyses of data from a RCT to evaluate
an online asthma management program for urban adoles-
cents with asthma, students who were randomized to the
treatment group and met criteria for elevated depressive
symptoms had better controller medication adherence
when compared to a control group at 6-month follow
up. Adolescents without depressive symptoms at base-
line did not show statistically significant improvement in
controller medication adherence. Interventions aimed at
improving controller medication adherence as part of
asthma self-management programs may need to be tailored
for adolescents with depressive symptoms.
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